[go: up one dir, main page]

SG10201809457YA - Insulin receptor partial agonists - Google Patents

Insulin receptor partial agonists

Info

Publication number
SG10201809457YA
SG10201809457YA SG10201809457YA SG10201809457YA SG10201809457YA SG 10201809457Y A SG10201809457Y A SG 10201809457YA SG 10201809457Y A SG10201809457Y A SG 10201809457YA SG 10201809457Y A SG10201809457Y A SG 10201809457YA SG 10201809457Y A SG10201809457Y A SG 10201809457YA
Authority
SG
Singapore
Prior art keywords
partial agonists
insulin receptor
receptor partial
insulin
dimers
Prior art date
Application number
SG10201809457YA
Inventor
Songnian Lin
Lin Yan
Pei Huo
Dmitri Pissarnitski
Danqing Feng
Ravi Nargund
Yuping Zhu
Ahmet Kekec
Christina Madsen-Duggan
Zhi-Cai Shi
Zhicai Wu
Yingjun Mu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SG10201809457YA publication Critical patent/SG10201809457YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

INSULIN RECEPTOR PARTIAL AGONISTS OF THE DISCLOSURE Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed. 5 [No Fig Available] 10 [Fig 1]
SG10201809457YA 2014-11-21 2015-11-19 Insulin receptor partial agonists SG10201809457YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082857P 2014-11-21 2014-11-21
US201562242503P 2015-10-16 2015-10-16

Publications (1)

Publication Number Publication Date
SG10201809457YA true SG10201809457YA (en) 2018-11-29

Family

ID=54838417

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201809427SA SG10201809427SA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG10201809428UA SG10201809428UA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG10201809457YA SG10201809457YA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG11201704064TA SG11201704064TA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201809427SA SG10201809427SA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG10201809428UA SG10201809428UA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201704064TA SG11201704064TA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists

Country Status (26)

Country Link
US (4) US10017556B2 (en)
EP (4) EP3666792B1 (en)
JP (5) JP6484337B2 (en)
KR (2) KR102049647B1 (en)
CN (2) CN112494656B (en)
AR (1) AR102712A1 (en)
AU (3) AU2015349890B2 (en)
CA (2) CA2966765C (en)
CL (3) CL2017001288A1 (en)
CO (1) CO2017004976A2 (en)
CR (1) CR20170208A (en)
DO (1) DOP2017000124A (en)
EA (1) EA036714B1 (en)
ES (2) ES3004386T3 (en)
GT (1) GT201700104A (en)
IL (1) IL252257A0 (en)
MX (3) MX2017006651A (en)
NI (1) NI201700060A (en)
PE (1) PE20170957A1 (en)
PH (1) PH12017500935A1 (en)
SG (4) SG10201809427SA (en)
SV (1) SV2017005445A (en)
TN (1) TN2017000178A1 (en)
TW (1) TW201625673A (en)
WO (1) WO2016081670A2 (en)
ZA (1) ZA201703238B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689383B2 (en) 2014-08-04 2020-06-23 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
SG10201809427SA (en) 2014-11-21 2018-11-29 Merck Sharp & Dohme Insulin receptor partial agonists
AR105616A1 (en) 2015-05-07 2017-10-25 Lilly Co Eli FUSION PROTEINS
US10953076B2 (en) 2016-05-24 2021-03-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and GLP-1 analogues
US10689430B2 (en) 2016-05-25 2020-06-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
WO2018077851A1 (en) * 2016-10-24 2018-05-03 Novo Nordisk A/S Bioassay for insulin formulations
TW201917134A (en) 2017-08-17 2019-05-01 丹麥商諾佛 儂迪克股份有限公司 Novel acylated insulin analogues and uses thereof
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EA202190416A1 (en) 2018-08-02 2021-06-23 Дайн Терапьютикс, Инк. MUSCULAR-SPECIFIC COMPLEXES AND THEIR APPLICATION FOR THE TREATMENT OF SHOULDER-SCAPULAR-FACIAL MUSCULAR DYSTROPHY
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
CN112898172B (en) * 2019-12-04 2022-05-31 中国科学院大连化学物理研究所 Synthesis method of amphiphilic functional group compound capable of being enzymolyzed by carboxypeptidase
PE20230240A1 (en) 2019-12-20 2023-02-07 Nuevolution As ACTIVE COMPOUNDS AGAINST NUCLEAR RECEPTORS
MX2022007265A (en) 2019-12-20 2022-09-09 Nuevolution As Compounds active towards nuclear receptors.
JP7713954B2 (en) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ Compounds active against nuclear receptors
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
US20250051416A1 (en) * 2020-08-26 2025-02-13 Merck Sharp & Dohme Llc Insulin receptor partial agonists
WO2022046739A1 (en) * 2020-08-26 2022-03-03 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
CN116457015A (en) * 2020-09-03 2023-07-18 达因疗法公司 Method for preparing protein-oligonucleotide complexes
US20230330562A1 (en) * 2020-09-03 2023-10-19 Dyne Therapeutics, Inc. Methods of preparing protein-oligonucleotide complexes
WO2022055877A2 (en) * 2020-09-09 2022-03-17 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2024525608A (en) 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド Muscle-targeting complexes and formulations for treating dystrophinopathy
CN119183457A (en) 2022-04-15 2024-12-24 达因疗法公司 Muscle-targeted compounds and formulations for the treatment of myotonic dystrophy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
AU4550699A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding agents that modulate the 5-ht transporter
DE19908041A1 (en) 1999-02-24 2000-08-31 Hoecker Hartwig Covalently bridged insulin dimers
KR100449454B1 (en) 2000-10-02 2004-09-21 이현철 Vector for Curing Diabetes Mellitus Containing Gene of Single-chain Insulin Analog
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
ES2346646T5 (en) 2002-05-30 2018-02-15 The Scripps Research Institute Copper catalyzed ligation of azides and acetylenes
KR100507796B1 (en) 2003-04-03 2005-08-17 한미약품 주식회사 Peg-biologically active polypeptide homodimer conjugate having enhanced half life in blood and process for the preparation thereof
AU2004295023A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
US20090197800A1 (en) 2004-10-27 2009-08-06 Novo Nordisk A/S Insulin Receptor Binding Peptides with Non-Insulin Gene Activation Profiles and Uses Thereof
DK1812031T3 (en) 2004-11-01 2015-09-14 Univ California Compositions and methods for the modification of biomolecules
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
US20090069216A1 (en) 2006-02-21 2009-03-12 Novo Nordisk A/S Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP1996709A2 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
US20090069215A1 (en) 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
JP5256199B2 (en) 2006-08-07 2013-08-07 テヴァ バイオファーマシューティカルズ ユーエスエー，インコーポレーティッド Albumin-insulin fusion protein
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
CA2722168A1 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
TWI394580B (en) 2008-04-28 2013-05-01 Halozyme Inc Super fast-acting insulin compositions
PL3228320T3 (en) * 2008-10-17 2020-06-01 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
CA2747490C (en) 2008-12-19 2017-02-14 Indiana University Research And Technology Corporation Insulin analogs
WO2010080609A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2011059895A1 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Hexa mutations
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8255297B2 (en) 2010-07-20 2012-08-28 Facebook, Inc. Creation, redemption, and accounting in a virtual currency system
JP2013540771A (en) * 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス Novel N-terminally modified insulin derivative
AU2012328407A1 (en) * 2011-10-27 2014-05-22 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
CA2886228A1 (en) * 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
CA2904198A1 (en) 2013-03-15 2014-09-18 Universite De Geneve Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
US9884125B2 (en) * 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
WO2015073575A2 (en) * 2013-11-12 2015-05-21 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
SG11201605680PA (en) 2014-01-20 2016-09-29 Hanmi Pharm Ind Co Ltd Long-acting insulin and use thereof
SG10201809427SA (en) * 2014-11-21 2018-11-29 Merck Sharp & Dohme Insulin receptor partial agonists

Also Published As

Publication number Publication date
CL2019001144A1 (en) 2019-07-19
US20180291078A1 (en) 2018-10-11
CA2966765C (en) 2020-04-14
PE20170957A1 (en) 2017-07-13
CN108064173A (en) 2018-05-22
KR102049647B1 (en) 2019-11-29
AU2018211207B2 (en) 2020-04-09
EP3666792A3 (en) 2020-07-29
JP2019014734A (en) 2019-01-31
CR20170208A (en) 2017-07-17
TW201625673A (en) 2016-07-16
US10800827B2 (en) 2020-10-13
US20170355743A1 (en) 2017-12-14
AU2018211207A1 (en) 2018-08-16
WO2016081670A2 (en) 2016-05-26
EP3221343A2 (en) 2017-09-27
AR102712A1 (en) 2017-03-22
EP3666792A2 (en) 2020-06-17
EP3666792B1 (en) 2024-12-18
ES3004386T3 (en) 2025-03-12
EP3660041A1 (en) 2020-06-03
AU2015349890B2 (en) 2018-08-30
JP6703068B2 (en) 2020-06-03
GT201700104A (en) 2018-11-27
CN112494656B (en) 2024-01-30
EP3660040B1 (en) 2025-06-18
JP2019014735A (en) 2019-01-31
EP3660040A3 (en) 2020-07-29
CN112494656A (en) 2021-03-16
IL252257A0 (en) 2017-07-31
JP2020097572A (en) 2020-06-25
EP3221343B1 (en) 2020-09-16
SV2017005445A (en) 2018-04-04
MX2020014120A (en) 2021-03-25
CN108064173B (en) 2021-05-18
EA036714B1 (en) 2020-12-10
EP3660040A2 (en) 2020-06-03
CA2966765A1 (en) 2016-05-26
US10017556B2 (en) 2018-07-10
KR20170084300A (en) 2017-07-19
JP2019011357A (en) 2019-01-24
US20170107268A1 (en) 2017-04-20
SG10201809427SA (en) 2018-11-29
PH12017500935A1 (en) 2017-11-27
EA201791117A1 (en) 2017-11-30
ZA201703238B (en) 2018-05-30
JP6943825B2 (en) 2021-10-06
TN2017000178A1 (en) 2018-10-19
BR122024000898A2 (en) 2024-02-27
JP2018501203A (en) 2018-01-18
AU2015349890A1 (en) 2017-06-01
CL2017001288A1 (en) 2017-12-15
BR112017010481A8 (en) 2023-04-11
MX2017006651A (en) 2017-08-21
BR122024000903A2 (en) 2024-02-27
AU2018211208B2 (en) 2020-09-10
KR102101136B1 (en) 2020-04-14
KR20190069622A (en) 2019-06-19
CA3014641C (en) 2020-08-18
CO2017004976A2 (en) 2017-10-10
CL2019001143A1 (en) 2019-07-19
ES2946247T3 (en) 2023-07-14
EP3660041B1 (en) 2023-04-19
AU2018211208A1 (en) 2018-08-16
WO2016081670A3 (en) 2016-08-04
SG10201809428UA (en) 2018-11-29
NI201700060A (en) 2017-07-18
SG11201704064TA (en) 2017-06-29
CA3014641A1 (en) 2016-05-26
US20190092833A1 (en) 2019-03-28
JP6931033B2 (en) 2021-09-01
US10183981B2 (en) 2019-01-22
BR112017010481A2 (en) 2018-04-03
DOP2017000124A (en) 2017-08-15
MX2020014121A (en) 2021-03-25
JP6484337B2 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
SG10201809427SA (en) Insulin receptor partial agonists
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2021014955A (en) Subcutaneous formulations of anti-cd38 antibodies and their uses.
PH12016502142A1 (en) Anti-ptk7 antibody-drug conjugates
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
MA40579A (en) Anti-cll-1 antibodies and immunoconjugates
MY193661A (en) Anti-tim3 antibodies and methods of use
MX2020004073A (en) Seed train processes and uses thereof.
MX2016015162A (en) Anti-gpc3 antibodies and immunoconjugates.
MX2020004419A (en) Modified meningococcal fhbp polypeptides.
MX2020012893A (en) Protein formulations.
MX2016016233A (en) Anti-lgr5 antibodies and uses thereof.
MX2019011297A (en) Insulin analog complex with reduced affinity for insulin receptor and use thereof.
MY167350A (en) Fat-and-oil composition and chocolate
MA40642A (en) Novel peptide derivatives and uses thereof
NZ719451A (en) Glucagon analog for treatment of severe hypoglycemia
EA201991576A1 (en) PARTIAL INSULIN RECEPTOR AGONISTS
NZ744340A (en) Anti-jagged1 antibodies and methods of use
UA99992U (en) 2,34-tetrahydropyridin-6-thiolate